Gossamer Bio Inc (NASDAQ: GOSS) stock jumped 1.83% on Monday to $0.84 against a previous-day closing price of $0.82. With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8594 whereas the lowest price it dropped to was $0.8000. The 52-week range on GOSS shows that it touched its highest point at $9.55 and its lowest point at $0.45 during that stretch. It currently has a 1-year price target of $5.68. Beta for the stock currently stands at 1.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GOSS was up-trending over the past week, with a rise of 33.10%, but this was up by 54.72% over a month. Three-month performance dropped to -18.63% while six-month performance fell -42.60%. The stock lost -90.81% in the past year, while it has lost -61.38% so far this year. A look at the trailing 12-month EPS for GOSS yields -1.76 with Next year EPS estimates of -0.81. For the next quarter, that number is -0.21. This implies an EPS growth rate of 54.34% for this year and 34.77% for next year. EPS is expected to grow by 5.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -92.43%.
Float and Shares Shorts:
At present, 225.41 million GOSS shares are outstanding with a float of 182.30 million shares on hand for trading. On Oct 30, 2023, short shares totaled 20.03 million, which was 8.88% higher than short shares on Sep 28, 2023. In addition to Mr. Faheem Hasnain as the firm’s Co-Founder, CEO, President & Chairman, Mr. Bryan Giraudo serves as its COO & CFO.
Through their ownership of 90.37% of GOSS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 8.34% of GOSS, in contrast to 7.85% held by mutual funds. Shares owned by individuals account for 66.76%. As the largest shareholder in GOSS with 4.96% of the stake, The Vanguard Group, Inc. holds 11,167,311 shares worth 11,167,311. A second-largest stockholder of GOSS, EcoR1 Capital, LLC, holds 9,195,404 shares, controlling over 4.08% of the firm’s shares. Octagon Capital Advisors LP is the third largest shareholder in GOSS, holding 8,187,883 shares or 3.63% stake. With a 3.48% stake in GOSS, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 7,830,376 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.27% of GOSS stock, is the second-largest Mutual Fund holder. It holds 2,866,985 shares valued at 1.43 million. iShares Biotechnology ETF holds 0.59% of the stake in GOSS, owning 1,324,512 shares worth 0.66 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GOSS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With GOSS analysts setting a high price target of $15.00 and a low target of $0.50, the average target price over the next 12 months is $5.68. Based on these targets, GOSS could surge 1685.71% to reach the target high and fall by -40.48% to reach the target low. Reaching the average price target will result in a growth of 576.19% from current levels.
Summary of Insider Activity:
Insiders traded GOSS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 1,609,772 while 22,970 shares were sold.